Treatment of non-small cell bronchogenic carcinoma with vinblastine and mitomycin: A southwest oncology group study

J. K. Weick, J. M. Rainey, R. B. Livingston, L. H. Baker, R. M. O'Bryan, T. T. Chen

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Forty-five patients with stage III M1 non-small cell bronchogenic carcinoma were treated with vinblastine (1 mg/m2 by iv bolus twice a day on 2 consecutive days) plus mitomycin (10 mg/m2 on Day 1). This treatment was repeated at 3-week intervals for three courses. Consolidation therapy with doxorubicin and cisplatin at doses of 50 mg/m2 each was administered to responders every 4 weeks for two courses, with subsequent vinblastine and mitomycin maintenance therapy every 6 weeks. Eleven partial remissions (24%) were achieved, with a median duration of remission of 16 weeks (range, 8-32) and a median survival of 19 weeks. No differences were seen in median duration or remission or survival by cell type or performance status.

Original languageEnglish (US)
Pages (from-to)583-585
Number of pages3
JournalCancer Treatment Reports
Volume69
Issue number6
StatePublished - Sep 25 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of non-small cell bronchogenic carcinoma with vinblastine and mitomycin: A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this